This review proposes that K2's large adverse impact prevalence is due, no less than partially, to distinct JWH-018 metabolite action within the cannabinoid 1 receptor (CB1R), and implies that metabolites of most prescription drugs, but not the carboxy metabolite, keep in vitro and in vivo activity at CB1Rs. Spice is https://eam220197520.digiblogbox.com/56276852/new-step-by-step-map-for-synthetic-cannabinoids-eam2201